MARKET

VRDN

VRDN

Viridian Therapeutics Inc
NASDAQ
32.02
-0.44
-1.36%
After Hours: 32.02 0 0.00% 17:55 12/05 EST
OPEN
32.44
PREV CLOSE
32.46
HIGH
32.97
LOW
31.95
VOLUME
673.78K
TURNOVER
--
52 WEEK HIGH
33.34
52 WEEK LOW
9.90
MARKET CAP
3.06B
P/E (TTM)
-8.6054
1D
5D
1M
3M
1Y
5Y
1D
Viridian Therapeutics Grants Stock Options to New Employees as Inducement Awards
Reuters · 2d ago
VIRIDIAN THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 2d ago
Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza
Benzinga · 3d ago
VIRIDIAN THERAPEUTICS INC <VRDN.O>: WILLIAM BLAIR INITIATES COVERAGE WITH OUTPERFORM RATING
Reuters · 4d ago
Viridian Therapeutics initiated with an Outperform at William Blair
TipRanks · 4d ago
Weekly Report: what happened at VRDN last week (1124-1128)?
Weekly Report · 6d ago
Viridian Therapeutics Price Target Announced at $41.00/Share by Truist Securities
Dow Jones · 11/24 18:12
Truist Financial Initiates a Buy Rating on Viridian Therapeutics (VRDN)
TipRanks · 11/24 12:26
More
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Webull offers Viridian Therapeutics Inc stock information, including NASDAQ: VRDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRDN stock methods without spending real money on the virtual paper trading platform.